Irene Aguilera-Ventura

Irene Aguilera-Ventura

Auto-generated profile, based on publicly available information

Irene Aguilera-Ventura

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
LSLucía Suanes-Cobos
Lucía Suanes-Cobos
IAIrene Aguilera-Ventura
Irene Aguilera-Ventura
MTMiguel Torres-Ramos
Miguel Torres-Ramos
ASAlejandra Serrano-Yubero
Alejandra Serrano-Yubero
CFClaudia Moreno Fernández-Aliseda
Claudia Moreno Fernández-Aliseda
MCMarco Antonio Calzado Canale
Marco Antonio Calzado Canale
Posttranslational modifications, such as ubiquitination and phosphorylation, play pivotal roles in regulating protein stability in response to cellular stress. Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) and ubiquitin-specific peptidase 28 (USP28) are critical regulators of cell cycle progression, DNA damage response, and oncogenic signaling. However, their functional interplay remains largely unexplored. Here, we describe a novel bidirectional regulatory mechanism between DYRK2 and USP28 that integrates DNA damage response and ubiquitin-mediated protein degradation. We demonstrate that DYRK2 phosphorylates USP28, promoting its ubiquitination and proteasomal degradation in a kinase activity-independent manner, thereby contributing to the maintenance of oncogenic protein homeostasis. Conversely, USP28 functions as a deubiquitinase for DYRK2, stabilizing its protein levels and enhancing its kinase activity. Notably, we show that DYRK2 interacts and co-localizes with USP28, with the 521–541 DYRK2 region, particularly residue T525, playing a crucial role in USP28-mediated DYRK2 stabilization. Functionally, this reciprocal regulation modulates p53 signaling, influencing apoptotic responses to DNA damage. DYRK2-mediated phosphorylation of p53 at S46 is significantly reduced upon USP28 depletion, suggesting that USP28 facilitates DYRK2-dependent apoptosis. Additionally, our results highlight a complex regulatory axis involving USP28 and DYRK2, with implications for oncogenic cell death and genomic stability. Overall, our findings uncover a novel feedback loop in which DYRK2 and USP28 dynamically regulate each other to control proto-oncoprotein homeostasis and DNA damage signaling. This interplay offers potential therapeutic opportunities for targeting cancers with dysregulated ubiquitination and genomic instability.

12 January 2026 in Cancer and Metastasis Reviews
Verified
Journal Article
Open access
PDF file
LSLucía Suanes-Cobos
Lucía Suanes-Cobos
MTMiguel Torres-Ramos
Miguel Torres-Ramos
IAIrene Aguilera-Ventura
Irene Aguilera-Ventura
ASAlejandra Serrano-Yubero
Alejandra Serrano-Yubero
MCMarco Antonio Calzado Canale
Marco Antonio Calzado Canale
Dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) is emerging as a pivotal player in cancer biology due to its pleiotropic cellular roles, functioning either as a tumor suppressor or an oncogene in a tissue- and genotype-dependent manner. DYRK2 regulates critical processes including cell cycle progression, DNA damage response, and stress signaling. As a tumor suppressor, DYRK2 facilitates the degradation of oncogenic proteins (e.g., c-Myc, SNAIL, TERT) and enhances apoptosis via p53 activation. Loss of DYRK2 has been associated with poor prognosis and chemoresistance in cancers such as colorectal, breast, and liver. Conversely, DYRK2 overexpression in certain tumors, including triple-negative breast cancer and ovarian carcinoma, supports oncogenic roles by enhancing proteasome function, promoting epithelial-mesenchymal transition, and contributing to therapy resistance. This functional dichotomy is modulated by post-translational modifications, microenvironmental stress, epigenetic regulation, subcellular localization, and interaction with protein complexes, underscoring the complexity of DYRK2 regulation. Therapeutically, DYRK2 represents a promising but context-sensitive target, with inhibitors showing efficacy in preclinical models of proteasome-addicted cancers, although precise biomarkers and cancer subtype stratification remain critical. Future directions include refining in vivo models and delineating the role of DYRK2 in cancer stem cell dynamics and immune modulation, emphasizing that understanding its context-dependent activity is essential to exploit its full therapeutic potential in oncology.